T-cell therapy of cytomegalovirus and human immunodeficiency virus infection

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue TOPIC T3, 2000, Pages 35-43

  Riddell, S R ^a,b   Greenberg, P D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034091181     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Greenberg, P. D. & Riddell, S. R. (1999). Deficient cellular immunity - finding and fixing the defects. Science 285, 546-51.
2. Meyers, J. D., Flournoy, N. & Thomas, E. D. (1986). Risk factors for cytomegalovirus infection after human marrow transplantation. Journal of Infectious Diseases 153, 478-88.
3. + cytotoxic T cell therapy of cytomegalovirus and HIV infection. Current Opinion in Immunology 5, 484-91.
4. Furtado, M. R., Callaway, D. S., Phair, J. P., Kunstman, K. J., Stanton, J. L., Macken, C. A. et al. (1999). Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New England Journal of Medicine 340, 1614-22.
5. Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S. et al. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New England Journal of Medicine 340, 1605-13.
6. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine 5, 512-7.
7. Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G. & Meyers, J. D. (1993). Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Annals of Internal Medicine 118, 173-8.
8. Boeckh, M., Riddell, S. R., Cunningham, T., Myerson, D., Flowers, M. & Bowden, R. (1996). Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses. (Abstract 1195) Blood 88, Suppl., 302a.
9. Ringden, O., Pihlstedt, P., Volin, L., Nikoskelainen, J., Lonnqvist, B., Ruutu, P. et al. (1987). Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomised trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplantation 2, 299-305.
10. Emanuel, D., Cunningham, I., Jules-Elysee, K., Brochstein, J. A., Kernan, N. A., Laver, J. et al. (1988). Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Annals of Internal Medicine 109, 777-82.
11. Reddehase, M. J., Mutter, W., Munch, K., Buhring, H. J. & Koszinowski, U. H. (1987). CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. Journal of Virology 61, 3102-8.
12. Quinnan, G. V., Kirmani, N., Rook, A. H., Manischewitz, J. F., Jackson, L., Moreschi, G. et al. (1982). Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. New England Journal of Medicine 307, 7-13.
13. Reusser, P., Riddell, S. R., Meyers, J. D. & Greenberg, P. D. (1991). Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78, 1373-80.
14. Li, C. R., Greenberg, P. D., Gilbert, M. J., Goodrich, J. M. & Riddell, S. R. (1994). Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83, 1971-9.
15. Yewdell, J. W. & Bennink, J. R. (1999). Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annual Review of Immunology 17, 51-88.
16. Riddell, S. R., Rabin, M., Geballe, A. P., Britt, W. J. & Greenberg, P. D. (1991). Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. Journal of Immunology 146, 2795-804.
17. + virus-specific cytotoxic T lymphocytes. Journal of Medical Virology 43, 103-10.
18. Wills, M. R., Carmichael, A. J., Mynard, K., Jin, X., Weekes, M. P., Plachter, B. et al. (1996). The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. Journal of Virology 70, 7569-79.
19. Riddell, S. R. & Greenberg, P. D. (1997). T cell therapy of human CMV and EBV infection in immunocompromised hosts. Reviews in Medical Virology 7, 181-92.
20. Ploegh, H. L. (1998). Viral strategies of immune evasion. Science 280, 248-53.
21. + T cells. Nature Medicine 5, 1039-43.
22. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D. et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine 333, 1038-44.
23. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E. & Greenberg, P. D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-41.
24. Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J., Suresh, M., Altman, J. D. et al. (1998). Viral immune evasion due to persistence of activated T cells without effector function. Journal of Experimental Medicine 188, 2205-13.
25. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. Journal of Virology 68, 6103-10.
26. Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S. et al. (1998). Quantitation of HIV-1-specific cylotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-6.
27. + T cell responses associated with control of viremia. Science 278, 1447-50.
28. Klein, M. R., van Baalen, C. A., Holwerda, A. M., Kerkhof Garde, S. R., Bende, R. J., Keet, I. P. et al. (1995). Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. Journal of Experimental Medicine 181, 1365-72.
29. Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D. & Baltimore, D. (1998). HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397-401.
30. Dougherty, J. P. & Temin, H. M. (1988). Determination of the rate of base-pair substitution and insertion mutations in retrovirus replication. Journal of Virology 62, 2817-22.
31. Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Peffer, N., Meyers, H. et al. (1997). Antiviral pressure exerted by HIV-1 -specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Medicine 3, 205-11.
32. Goulder, P. J., Phillips, R. E., Colbert, R. A., McAdam, S., Ogg, G., Nowak, M. A. et al. (1997). Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Medicine 3, 212-7.
33. Klenerman, P., Rowland-Jones, S., McAdam, S., Edwards, J., Daenke, S., Lalloo, D. et al. (1994). Cytotoxic T-cell activity antagonised by naturally occurring HIV-1 Gag variants. Nature 369, 403-7.
34. Pantaleo, G. & Fauci, A. S. (1996). Immunopathogenesis of HIV infection. Annual Review of Microbiology 50, 825-54.
35. Chun, T. W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H. et al. (1997). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-8.
36. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Medicine 5, 518-25.
37. Lisziewicz, J., Sun, D., Smythe, J., Lusso, P., Lori, F., Louie, A. et al. (1993). Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proceedings of the National Academy of Sciences, USA 90, 8000-4.
38. Sarver, N., Cantin, E. M., Chang, P. S., Zaia, J. A., Ladne, P. A., Stephens, D. A. et al. (1990). Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-5.
39. Levy-Mintz, P., Duan, L., Zhang, H., Hu, B., Dornadula, G., Zhu, M. et al. (1996). Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. Journal of Virology 70, 8821-32.
40. Brodie, S. J., Lewinsohn, D. A., Patterson, B. K., Jiyamapa, D., Krieger, J., Corey, L. et al. (1999). In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Medicine 5, 34-41.
41. + CTL clones is limited by elimination due to encounter with HIV-infected targets. Journal of Immunology 163, 861-7.
42. Riddell, S. R. & Greenberg, P. D. (1995). Principles for adoptive T cell therapy of human viral diseases. Annual Review of Immunology 13, 545-86.